A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO ESTIMATE THE EFFECT OF REPEAT-DOSE RIFAMPIN ON THE PHARMACOKINETICS OF PF-04965842 IN HEALTHY SUBJECTS
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2019
Price : $35 *
At a glance
- Drugs Abrocitinib (Primary) ; Rifampicin
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 02 Jan 2019 Status changed from recruiting to completed.
- 07 Nov 2018 Planned End Date changed from 16 Nov 2018 to 1 Dec 2018.
- 07 Nov 2018 Planned primary completion date changed from 14 Nov 2018 to 1 Dec 2018.